Emergency: U.S. declares monkeypox a public health emergency
The Direxion Daily S&P Biotech Bull 3X Shares fund provides exposure to a large range of high-performing biotechnology companies in the US. Managed by Direxion, which is headquartered in Milwaukee, Wisconsin this fund was established in May 2015.
The key objective of the Direxion Daily S&P Biotech Bull 3X Shares ETF is to provide 300% of the daily investment performance of the S&P Biotechnology Select Industry Index, but this fund should not be expected to provide these results for periods greater than a single day. All the companies held by this fund are part of the S&P 500, which includes large companies listed on stock exchanges within the United States. The fund generally invests the majority of its assets in stocks for companies that are listed in the index. The base currency for this fund is USD.
Stock for the Direxion Daily S&P Biotech Bull 3X Shares ETF is listed on the NYSE under the ticker LABU.US. This fund only includes investments in the biotechnology industry. This fund is non-diversified. As of 10 December 2021, some of the fund's top holdings include Acceleron Phar/D, Cytokinetics, Sarepta Therapeutics Inc De, Seagen Inc., Tg Therapeutics, Seres Therapeutics, Chemocentryx, Dynavax Technologies, Iovance Biotherapeutics Inc., and Ironwood Pharma Class A.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.